Lexaria Bioscience Signs Contracts for Human Pilot Study of Oral DehydraTECH-Semaglutide

Kelowna, British Columbia — April 1, 2026 — Leads & Copy — Lexaria Bioscience Corp. (Nasdaq: LEXX) has signed contracts with a contract research organization (CRO) to conduct Human Pilot Study #7 (GLP-1-H26-7). The study will assess two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against commercially available Wegovy® tablets.

The company is preparing submissions to secure ethics approval from an independent review board. The study design is nearly complete and is anticipated to be a five-week parallel group design, examining three separate arms to evaluate safety, tolerability, and pharmacokinetic (PK) properties.

The study will compare salcaprozate sodium (“SNAC”)-inclusive DHT-sema tablet and capsule formulations to Wegovy® tablets under fasted pre-dose conditions. Lexaria aims to maintain the safety and tolerability observed in previous GLP-1 studies, such as GLP-1-H25-4, while achieving PK performance comparable to Rybelsus® and Wegovy®.

Successful study results would enhance Lexaria’s existing data, potentially attracting pharmaceutical partners interested in commercial relationships involving Lexaria’s DehydraTECH technology.

This study will explore DehydraTECH enhancements not previously evaluated, including the use of an oral tablet DHT-sema composition. Prior studies used capsule compositions. Novo Nordisk’s® Rybelsus® and Wegovy® oral semaglutide medications use tablets designed to adhere to the stomach lining and release agents to optimize semaglutide absorption.

Lexaria has attempted to mimic certain properties of the Rybelsus®/Wegovy® tablet delivery method in its DHT-sema tablets.

The Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, marking the first time these formulations are evaluated over a multi-dose, multi-week period in humans. The five-week study duration is designed to reach steady-state drug concentrations in the body.

Earlier DHT-sema human pilot studies in 2024 and 2025 that used SNAC but not tablets were limited to single-dose designs. Novo Nordisk’s Rybelsus® and Wegovy® are formulated with SNAC.

Lexaria will provide updates once ethics board approval is obtained and patient recruitment can commence. The study is fully funded from existing corporate resources.

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide.

Source: Lexaria Bioscience Corp.